| Chemical Properties | Back Directory | [Boiling point ]
456.711±48.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.280±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [solubility ]
DMF: 1 mg/ml; DMSO: 1 mg/ml | [form ]
A solid |
| Hazard Information | Back Directory | [Description]
Imiquimod-d9 is intended for use as an internal standard for the quantification of imiquimod by GC- or LC-MS. Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7; EC50 = 2.12 μM).1 It increases TNF-α and IL-12 p40 production in IFN-γ-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.2 Topical application of imiquimod (30 μl of 5% cream) increases TNF and IFN levels at the application site in hairless mice.3 Imiquimod dose-dependently increases serum levels of IFN-α in mice when administered by gavage.4 It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection.5 Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts. | [Uses]
Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2]. | [References]
1. Shukla, N.M., Mallardi, S.S., Mutz, C.A., et al. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues J. Med. Chem. 53(11),4450-4465(2010).
2. Hemmi, H., Kaisho, T., Takeuchi, O., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat. Immunol. 3(2),196-200(2002).
3. Imbertson, L.M., Beaurline, J.M., Couture, A.M., et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463 J. Invest. Dermatol. 110(5),734-739(1998).
4. Sidky, Y.A., Borden, E.C., Weeks, C.E., et al. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine Cancer Res. 52(13),3528-3533(1992).
5. Harrison, C.J., Jenski, L.J., Voychehovski, T., et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection Antiviral Res. 10(4-5),209-223(1988). |
|
|